TuisCGEN • NASDAQ
add
Compugen Ltd
Vorige sluiting
$1,41
Dagwisseling
$1,37 - $1,54
Jaarwisseling
$0,62 - $3,03
Markkapitalisasie
136,10Â m USD
Gemiddelde volume
262,37Â k
P/V-verhouding
79,29
Dividend-opbrengs
-
PrimĂŞre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Inkomste | 17,13 m | — |
Bedryfskoste | 9,04Â m | -14,99% |
Netto inkomste | 1,28Â m | 112,95% |
Netto winsgrens | 7,45 | — |
Wins per aandeel | 0,01 | 109,09% |
EBITDA | 4,62Â m | 143,92% |
Effektiewe belastingkoers | 77,92% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 112,71Â m | 95,99% |
Totale bates | 123,52Â m | 82,69% |
Totale aanspreeklikheid | 63,03Â m | 338,18% |
Totale ekwiteit | 60,49 m | — |
Uitstaande aandele | 89,54 m | — |
Prys om te bespreek | 2,07 | — |
Opbrengs op bates | 9,62% | — |
Opbrengs op kapitaal | 18,01% | — |
Kontantvloei
Netto kontantverandering
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 1,28Â m | 112,95% |
Kontant van bedrywe | — | — |
Kontant van beleggings | — | — |
Kontant van finansiering | — | — |
Netto kontantverandering | — | — |
Beskikbare kontantvloei | — | — |
Meer oor
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. Wikipedia
Gestig
10 Feb. 1993
Webwerf
Werknemers
68